Interruptions of antiretroviral therapy in human immunodeficiency virus infection: Are they detrimental to neurocognitive functioning?

Journal of NeuroVirology

Volumn 16, Issue 3, 2010, Pages 208-218

  Muñoz Moreno, Jose A ^a,b   Fumaz, Carmina R ^a,b   Prats, Anna ^a,b   Ferrer, Maria J ^a,b   Negredo, Eugènia ^a,b   Pérez Álvarez, Nria ^a,c   Molt, José ^a,b   Gómez, Guadalupe ^c   Garolera, Maite ^d   Clotet, Bonaventura ^a,b,e  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c UNIVERSITAT POLITÈCNICA DE CATALUNYA   (Spain)

^d Brain   (Spain)

^e IrsiCaixa Foundation   (Spain)

Author keywords

Antiretroviral therapy; HIV infection; Neurocognitive functioning; Neuropsychological assessment; Treatment interruption

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; ANXIETY DISORDER; ARTICLE; ATTENTION; BECK DEPRESSION INVENTORY; CLINICAL FEATURE; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DEMOGRAPHY; DEPRESSION; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; MALE; NERVOUS SYSTEM FUNCTION; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; SCORING SYSTEM; STATE TRAIT ANXIETY INVENTORY; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VIRUS LOAD; WECHSLER INTELLIGENCE SCALE; WORKING MEMORY;

ADULT; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COGNITION DISORDERS; CROSS-SECTIONAL STUDIES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PREVALENCE; SEXUALLY TRANSMITTED DISEASES; SUBSTANCE WITHDRAWAL SYNDROME; TREATMENT REFUSAL;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 77953220270     PISSN: 13550284     EISSN: None     Source Type: Journal    
DOI: 10.3109/13550281003767710     Document Type: Article

References (73)

1. Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, Clifford DB, Cinque P, Epstein LG, Goodkin K, Gisslen M, Grant I, Heaton RK, Joseph J, Marder K, Marra CM, McArthur JC, Nunn M, Price RW, Pulliam L, Robertson KR, Sacktor N, Valcour V, Wojna VE (2007). Updated research nosology for HIV-associated neurocognitive disorders. Neurology 69: 1789-1799.
2. Arendt G, Nolting T, Frisch C, Husstedt IW, Gregor N, Koutsilieri E, Maschke M, Angerer A, Obermann M, Neuen-Jacob E, Adams O, Loeffert S, Riederer P, ter Meulen V, Sopper S; German Competence Network HIV/AIDS (2007). Intrathecal viral replication and cerebral deficits in different stages of human immunodeficiency virus disease. J NeuroVirol 13: 225-232.
3. Avison MJ, Nath A, Greene-Avison R, Schmitt FA, Bales RA, Ethisham A, Greenberg RN, Berger JR (2004). Inflammatory changes and breakdown of microvascular integrity in early human immunodeficiency virus dementia. J NeuroVirol 10: 223-232.
4. Beck AT, Rush AJ, Shaw BF, Emery G (1979). Cognitive therapy of depression. New York, NY: Guilford Press.
5. Beck AT, Steer RA, Brown GK (1996). Beck Depression Inventory: manual BDI-II. New York, NY: Psychological Corporation.
6. Becker JT, Lopez OL, Dew MA, Aizenstein HJ (2004). Prevalence of cognitive disorders differs as a function of age in HIV virus infection. AIDS 18: S11-S18.
7. Benton AL, Hamsher K, Sivan AB (1994). Multilingual Aphasia Examination. Iowa City, IA: AJA Associates.
8. Berger JR, Nath A, Greenberg RN, Andersen AH, Greene RA, Bognar A, Avison MJ (2000). Cerebrovascular changes in the basal ganglia with HIV dementia. Neurology 54: 921-926.
9. Cardiello PG, Hassink E, Ananworanich J, Srasuebkul P, Samor T, Mahanontharit A, Ruxrungtham K, Hirschel B, Lange J, Phanuphak P, Cooper DA (2005). A prospective, randomized trial of structured treatment interruption for patients with chronic HIV type 1 infection. Clin Infect Dis 40: 594-600.
10. Castelo JM, Sherman SJ, Courtney MG, Melrose RJ, Stern CE (2006). Altered hippocampal-prefrontal activation in HIV patients during episodic memory encoding. Neurology 66: 1688-1695.
11. Childers ME, Woods SP, Letendre S, McCutchan JA, Rosario D, Grant I, Mindt MR, Ellis RJ (2008). Cognitive functioning during highly active antiretroviral therapy interruption in human immunodeficiency virus type 1 infection. J NeuroVirol 18: 1-8.
12. Clinical Trial of CNS-targeted HAART (CIT2) 2009). ClinicalTrials.gov Identifier: NCT00624195. December 2009. Available at: http://www.clinicaltrials. gov/ct2/show/study/NCT00624195?term=CIT+2+hiv&rank=1. Accessed January 27 2010.
13. Cohen J (1988). Statistical power analysis for the behavioral sciences, 2nd ed. Hillsdale, NJ: Erlbaum.
14. DX). Toronto, Canada: Multi-Health Systems Inc.
15. Cysique LA, Maruff P, Brew BJ (2004). Prevalence and pattern of neuropsychological impairment in human immunodeficiency virus-infected/acquired immunodeficiency syndrome (HIV/AIDS) patients across pre-and post-highly active antiretroviral therapy eras: a combined study of two cohorts. J NeuroVirol 10: 350-357.
16. Cysique LA, Maruff P, Brew BJ (2006). Variable benefit in neuropsychological function in HIV-infected HAART-treated patients. Neurology 66: 1447-1450.
17. Danel C, Moh R, Minga A, Anzian A, Ba-Gomis O, Kanga C, Nzunetu G, Gabillard D, Rouet F, Sorho S, Chaix ML, Eholié S, Menan H, Sauvageot D, Bissagnene E, Salamon R, Anglaret X; Trivacan ANRS 1269 Trial Group (2006). CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in west Africa (Tri-vacan ANRS 1269 trial): a randomised trial. Lancet 367: 1981-1989.
18. Davey RT Jr, Bat N, Yoder C, Chun TW, Metcalf JA, Dewar R, Natarajan V, Lempicki RA, Adelsberger JW, Miller KD, Kovacs JA, Polis MA, Walker RE, Falloon J, Masur H, Gee D, Baseler M, Dimitrov DS, Fauci AS, Lane HC (1999). HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc Natl Acad Sci USA 96: 15109-15114.
19. Deeks SG, Wrin T, Liegler T, Hoh R, Hayden M, Barbour JD, Hellmann NS, Petropoulos CJ, McCune JM, Hellerstein MK, Grant RM (2001). Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med 344: 472-480.
20. Delis DC, Kramer JH, Kaplan E, Ober BA (2000). California Verbal Learning Test. New York, NY: The Psychological Corporation.
21. Ellis RJ, Childers ME, Zimmerman JD, Frost SD, Deutsch R, McCutchan JA; HIV. Neurobehavioral Research Center Group (2003). Human immunodeficiency virus-1 RNA levels in cerebrospinal fluid exhibit a set point in clinically stable patients not receiving antiretroviral therapy. J Infect Dis 187: 1818-1821.
22. Ellis RJ, Hsia K, Spector SA, Nelson JA, Heaton RK, Wallace MR, Abramson I, Atkinson JH, Grant I, McCutchan JA (1997). Cerebrospinal fluid human immunodeficiency virus type 1 RNA levels are elevated in neurocognitively impaired individuals with acquired immunodeficiency syndrome. HIV Neurobehavioral Research Center Group. Ann Neurol 42: 679-688.
23. Ellis RJ, Moore DJ, Childers ME, Letendre S, McCutchan JA, Wolfson T, Spector SA, Hsia K, Heaton RK, Grant I (2002). Progression to neuropsychological impairment in human immunodeficiency virus infection predicted by elevated cerebrospinal fluid levels of human immunodeficiency virus RNA. Arch Neurol 59: 923-928.
24. El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, Abrams D, Arduino RC, Babiker A, Burman W, Clumeck N, Cohen CJ, Cohn D, Cooper D, Darbyshire J, Emery S, Fätkenheuer G, Gazzard B, Grund B, Hoy J, Klingman K, Losso M, Markowitz N, Neuhaus J, Phillips A, Rappoport C; Strategies for Management of Antiretrovi-ral Therapy (SMART) Study Group (2006). CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 355: 2283-2296.
25. García F, Plana M, Ortiz GM, Bonhoeffer S, Soriano A, Vidal C, Cruceta A, Arnedo M, Gil C, Pantaleo G, Pumarola T, Gallart T, Nixon DF, Miró JM, Gatell JM (2001). The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection. AIDS 15: F29-F40.
26. Gladsjo JA, Schuman CC, Evans JD, Peavy GM, Miller SW, Heaton RK (1999). Norms for letter and category fluency: demographic corrections for age, education, and ethnicity. Assessment 6: 147-178.
27. Golden CJ (1978). Stroop Color and Word Test: a manual for clinical and experimental uses. Wood Dale, IL: Stoetling Company.
28. Golden CJ (2001). Stroop. Test de Colores y Palabras. Madrid: TEA Ediciones.
29. Harrigan PR, Whaley M, Montaner JS (1999). Rate of HIV-1 RNA rebound upon stopping antiretroviral therapy. AIDS 13: F59-62.
30. Heaton R, Franklin D, Clifford D, Woods S, Rivera M, Vigil O, Taylor M, Marcotte T, Atkinson H, Grant I; CHARTER Study Group (2009). HIV-associated neurocogni-tive impairment remains prevalent in the era of combination ART: The CHARTER Study. Presented at The 16th Conference on Retroviruses and Opportunistic Infections, February 8-11, 2009, Montreal, Canada. Abstract 154.
31. Hilsabeck RC, Castellon SA, Hinkin CH (2005). Neuropsy-chological aspects of coinfection with HIV and hepatitis C virus. Clin Infect Dis 41: S38-S44.
32. Hirschel B, Flanigan T (2009). Is it smart to continue to study treatment interruptions? AIDS 23, 757-759.
33. Knysz B, Gasiorowski J, Czarnecki M, Gladysz A (2005). Viral rebound syndrome in two HIV-1-positive patients after structured treatment interruption. Viral Immunol 18: 579-581.
34. Kongs SK, Thompson LL, Iverson GL, Heaton RK (1993). Wisconsin Card Sorting Test\64 card computerized version. Odessa, FL: Psychological Assessment Resources.
35. Letendre SL, Marquie-Beck J, Capparelli E, Best B, Clifford D, Collier AC, Gelman BB, McArthur JC, McCutchan JA, Morgello S, Simpson D, Grant I, Ellis RJ; CHARTER Group (2008). Validation of the CNS penetration-effec tiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 65: 65-70.
36. Letendre SL, McCutchan JA, Childers ME, Woods SP, Lazzaretto D, Heaton RK, Grant I, Ellis RJ; HNRC Group (2004). Enhancing antiretroviral therapy for human immunodeficiency virus cognitive disorders. Ann Neu-rol 56: 416-423
37. Maggiolo F, Airoldi M, Callegaro A, Martinelli C, Dolara A, Bini T, Gregis G, Quinzan G, Ripamonti D, Ravasio V, Suter F (2009). CD4 cell-guided scheduled treatment interruptions in HIV-infected patients with sustained immunologic response to HAART. AIDS 23: 799-807.
38. Maggiolo F, Ripamonti D, Gregis G, Quinzan G, Callegaro A, Suter F (2004). Effect of prolonged discontinuation of successful antiretroviral therapy on CD4 T cells: a controlled, prospective trial. AIDS 18: 439-446.
39. Marcondes MC, Flynn C, Huitron-Rezendiz S, Watry DD, Zandonatti M, Fox HS (2009). Early antiretroviral treatment prevents the development of central nervous system abnormalities in simian immunodeficiency virus-infected rhesus monkeys. AIDS 23: 1187-1195.
40. Matthews CG, Klove H (1964). Instruction manual for the Adult Neuropsychology Test Battery. Madison, WI: University of Wisconsin Medical School.
41. McCrossan M, Marsden M, Carnie FW, Minnis S, Hansoti B, Anthony IC, Brettle RP, Bell JE, Simmonds P (2006). An immune control model for viral replication in the CNS during presymptomatic HIV infection. Brain 129: 503-516.
42. Moltó J, Ruiz L, Romeu J, Martínez-Picado J, Negredo E, Tural C, Sirera G, Clotet B (2004). Influence of prior structured treatment interruptions on the length of time without antiretroviral treatment in chronically HIV-infected subjects. AIDS Res Hum Retroviruses 20: 1283-1288.
43. Muñoz-Moreno JA (2007). Neurocognitive and motor dis-ordersinHIVinfection.Assessment andinterventions. In: Research focus on cognitive disorders. (Eds: Plishe VN). Hauppauge, NY: Nova Science Publishers, 133-147.
44. Muñoz-Moreno JA, Fumaz CR, Ferrer MJ, Prats A, Negredo E, Garolera M, Pérez-Álvarez N, Moltó J, Gómez G, Clotet B (2008). Nadir CD4 cell count predicts neuro-cognitive impairment in HIV-infected patients. AIDS Res Hum Retroviruses 24: 1301-1307.
45. Muñoz-Moreno JA, Letendre S, McClernon D, Ellis R, Leblanc S, Rosario D, Clifford D, Collier A, Gelman B
46. Marra CM, McArthur J, McCutchan A, Morgello S, Simpson D, Franklin D, Heaton R, Grant I; CHARTER Study Group (2009). Persistent HIV in the central nervous system during treatment is associated with worse ART penetration and cognitive impairment. Presented at The 9th International Symposium on Neurovirology, June 2-6, 2009, Miami, Florida, USA. Abstract P130.
47. Oxenius, A, Price DA, Günthard HF, Dawson SJ, Fagard C, Perrin L, Fischer M, Weber R, Plana M, García F, Hirschel B, McLean A, Phillips RE (2002). Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection. Proc Natl Acad Sci USA 99: 13747-13752.
48. Panel on Clinical Practices for Treatment of HIV Infection convened by the Department of Health and Human Services (DHHS) 2009). Guidelines for the use of anti-retroviral agents in HIV-infected adults and adolescents. December 2009. Available at: http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL. pdf. Accessed January 27 2010.
49. Price RW, Deeks SG (2004). Antiretroviral drug treatment interruption in human immunodeficiency virus-infected adults: clinical and pathogenetic implications for the central nervous system. J NeuroVirol 10: S44-S51.
50. Reitan RM, Davidson LA (1974). Clinical neuropsychology: current status and applications. New York, NY: John Wiley & Sons.
51. Reitan RM, Wolfson D (1985a). Trail Making Test. The Halstead-Reitan Neuropsychological Test Battery. Tucson, AZ: Neuropsychology Press.
52. Reitan RM, Wolfson D (1985b). Grooved Pegboard. The Halstead-Reitan Extended Neuropsychological Test Battery. Tucson, AZ: Neuropsychology Press.
53. Robertson K, Su Z, Krambrink A, Evans S, Havlir V, Margolis D, Skiest D; ACTG 5170 team (2007). This is your brain off drugs: neurocognitive function before and after ART discontinuation in patients with high CD4 nadir (ACTG A5170). Presented at The 14th Conference on Retroviruses and Opportunistic Infections, February 25-28, Los Angeles, California, USA. Abstract 113.
54. Ruíz L, Paredes R, Gomez G, Romeu J, Domingo P, Perez-Alvarez N, Tambussi G, Llibre JM, Martínez-Picado J, Vidal F, Fumaz CR, Clotet B; TIBET Study Group (2007). Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patients. AIDS 21: 169-178.
55. Sacktor N, McDermott MP, Marder K, Schifitto G, Selnes OA, McArthur JC, Stern Y, Albert S, Palumbo D, Kieburtz K, De Marcaida JA, Cohen B, Epstein L (2002). HIV-associated cognitive impairment before and after the advent of combination therapy. J NeuroVirol 8: 136-142.
56. Sarmati L, Andreoni C, Nicastri E, Tommasi C, Buonomini A, D'Ettorre G, Corpolongo A, Dori L, Montano M, Volpi A, Narciso P, Vullo V, Andreoni M (2009). Prognostic factors of long-term CD4+count-guided interruption of antiretroviral treatment. J Med Virol 81: 481-487.
57. Scriba TJ, Zhang HT, Brown HL, Oxenius A, Tamm N, Fidler S, Fox J, Weber JN, Klenerman P, Day CL, Lucas M, Phillips RE (2005). HIV-1-specific CD4+ T cell turnover and activation increase upon viral rebound. J Clin Invest 115: 443-450.
58. Seminari E, De Silvestri A, Boschi A, Tinelli C (2008). CD4 + guided antiretroviral treatment interruption in HIV infection: a meta-analysis. AIDS Rev 10: 236-244.
59. Shapshak P, Segal DM, Crandall KA, Fujimura RK, Zhang BT, Xin KQ, Okuda K, Petito CK, Eisdorfer C, Goodkin K (1999). Independent evolution of HIV type 1 in different brain regions. AIDS Res Hum Retroviruses 15: 811-820.
60. Smith A (1973). Symbol Digit Modalities Test (SDMT). Los Angeles, CA: Western Psychological Services.
61. Smith A (2002). Test de Símbolos y Dígitos (SDMT). Madrid: TEA Ediciones.
62. Spielberger CD, Gorsuch RL, Lushene RE (1970). Manual for the State-Trait Anxiety Inventory. Palo Alto, CA: Consulting Psychologists Press.
63. Spudich SS, Huang W, Nilsson AC, Petropoulos CJ, Liegler TJ, Whitcomb JM, Price RW (2005). HIV-1 chemokine coreceptor utilization in paired cerebrospinal fluid and plasma samples: a survey of subjects with viremia. J Infect Dis 191: 890-898.
64. Steingrover R, PogÁny K, Fernandez Garcia E, Jurriaans S, Brinkman K, Schuitemaker H, Miedema F, Lange JM, Prins JM (2008). HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy. AIDS 22: 1583-1588.
65. Strategic Timing of Antiretroviral Treatment (START) (2009). ClinicalTrials.gov Identifier: NCT00867048. December 2009. Available at: http://www.clinical-trials.gov/ct2/show/NCT00867048?term=start+neuro- ologic+hiv&rank=1. Accessed January 27 2010.
66. Tebas P, Henry K, Mondy K, Deeks S, Valdez H, Cohen C, Powderly WG (2002). Effect of prolonged discontinuation of successful antiretroviral therapy on CD4+ T cell decline in human immunodeficiency virus-infected patients: implications for intermittent therapeutic strategies. J Infect Dis 186: 851-854.
67. Tozzi V, Balestra P, Bellagamba R, Corpolongo A, Salvatori MF, Visco-Comandini U, Vlassi C, Giulanelli M, Galgani S, Antinori A, Narciso P (2007). Persistence of neurop-sychologic deficits despite long-term highly active anti-retroviral therapy in patients with HIV-related neurocognitive impairment: prevalence and risk factors. J Acquir Immune Defic Syndr 45: 174-182. (Pubitemid 46869810)
68. Tozzi V, Balestra P, Lorenzini P, Bellagamba R, Galgani S, Corpolongo A, Vlassi C, Larussa D, Zaccarelli M, Noto P, Visco-Comandini U, Giulanelli M, Ippolito G, Antinori A, Narciso P (2005a). 1996 to 2002: results from an urban observational cohort. J NeuroVirol 11: 265-273
69. Tozzi V, Balestra P, Salvatori MF, Vlassi C, Liuzzi G, Giancola ML, Giulianelli M, Narciso P, Antinori A (2009). Changes in cognition during antiretroviral therapy: comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders. J Acquir Immune Defic Syndr 52: 56-63.
70. Tozzi V, Balestra P, Serraino D, Bellagamba R, Corpolongo A, Piselli P, Lorenzini P, Visco-Comandini U, Vlassi C, Quartuccio ME, Giulianelli M, Noto P, Galgani S, Ippolito G, Antinori A, Narciso P (2005b). Neurocogni-tive impairment and survival in a cohort of HIV-infected patients treated with HAART. AIDS Res Hum Retro-viruses 21: 706-713.
71. Tubiana R, Ghosn J, De-Sa M, Wirden M, Gautheret-Dejean A, Bricaire F, Katlama C (2002). Warning: antiretroviral treatment interruption could lead to an increased risk of HIV transmission. AIDS 16: 1083-1091.
72. Weschler D (1997). Wechsler Adult Intelligence Scale\Third Edition (WAIS-III). Administration and scoring manual. San Antonio, TX: The Psychological Corporation.
73. a Ed.). Madrid: TEA Ediciones.